Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. EYE | Salud Visual 2.0 | Scoop.it
From www.nature.com - January 14, 2014 6:55 AM

Eye (2014) 28, 9–16;

Kriechbaum K, Prager S, Mylonas G,  et al

PurposeThe objective was to compare retinal morphology and function following intravitreal injections of bevacizumab (Avastin) or triamcinolone (Volon A) in patients with early diabetic macular edema (DME).Patients and methodsThe study was planned as a randomized, prospective, interventional clinical trial.

....-After 6 months, rehabilitation of vision was comparable in both treatment arms, whereas at the final follow-up at month 12, BCVA was superior in the bevacizumab than in the triamcinolone sample. This may be related to cataract development following steroid treatment, as well as to substance-specific mechanisms within the angiogenic versusthe inflammatory cascade.